Advanced BioHealing Outlines Strategic Growth Plan to Set Professional Precedence

     Advanced BioHealing Inc (Westport, Conn) announced a strategic growth plan designed to continue the transformation of this former start-up company into the leading international regenerative medicine company. The company which manufactures and markets Dermagraft®, a bioengineered skin substitute that repairs tissue damage caused by disease or injury and supports the body’s natural healing process in patients with diabetic foot ulcers. To spur future growth, executive management has outlined a growth strategy to leverage current successes, develop its international presence, address new applications, and expand its product line. The three key growth initiatives are continuing the expansion of company sales, extending product use for multiple indications, and diversifying the product portfolio.

     The company is working with industry peers to promote regulatory, research, and reimbursement policies that foster innovation in regenerative medicine as relationships and will educate at-risk populations of senior citizens and patients suffering with diabetes. A corporate identity program designed to position the company as a leading regenerative medicine company complete with new logo, tagline, web site, and public relations campaign are now in place.

     Visit www.dermagraft.com for more information.

KCI Announces Expected Regulatory Approval to Enter Japanese Market

     Kinetic Concepts Inc (San Antonio, Tex) recently announced that in October, the Ministry of Health, Labor and Welfare (MHLW) will grant regulatory approval for the company to begin market development activities at the Pharmaceutical and Medical Devices Agency (PMDA) in Japan for its V.A.C.® Therapy product.

     The company anticipates that in October the MHLW will ensure that all necessary regulatory steps have been addressed before the application is taken to the Minister’s Office for a signature. Following regulatory approval, the company expects reimbursement will be provided in the first half of 2010. Once reimbursement approval is obtained, the company will officially begin commercializing the therapy in Japan. The company’s vision is to transform wound care in Japan by delivering advanced healing solutions and clinical know-how in a way that produces unparalleled outcomes.

     Visit www.kci1.com for more information.

Sigvaris Sponsors Compression Therapy and Venous Disease Focused Blog

     Sigvaris (Peachtree City, Ga) will sponsor a leg circulation, compression therapy and venous disease management blog (www.veinhealthforum.org) as a continuing education resource for medical professionals. Medical topics and content related to compression therapy and venous disease are added regularly to the blog site. Medical professionals and industry experts including Dr. Samuel Martin, FACS; Dr. Mark D. Forrestal, FACph, and Dr. Michael F. Burke, FACS, will assist in moderating and authoring content for the company-sponsored compression therapy and leg vein health medical forum.

     The company is pleased to sponsor the Leg Circulation and Vein Health Forum, which is a compression-industry first designed for healthcare professionals to secure information regarding vein issues, procedures, treatment, and management of this progressive disease.

     Visit www.sigvarisusa.com for more information.

Wound Management Technologies Completes Strategic Acquisition

     Wound Management Technologies Inc (Fort Worth, Tex) has completed the acquisition of BioPharma Management Technologies Inc, a privately held biotechnology company with a platform of proprietary and patented technologies for topical pain management and resorbable orthoses.

     BioPharma’s proprietary technologies and its future products are complementary to Wound Management Technologies’ major product CellerateRx®. CellerateRx is a collagen hydrolysate polypeptid whose patented collagen fragments, which are a fraction of the size of the native collagen molecules and particles found in other products, deliver the benefits of collagen to the body immediately. The polypeptid is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first- and second-degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. Under the terms of the agreement, BioPharma is now a wholly owned subsidiary of Wound Management Technologies in exchange for 4,500,000 shares of Wound Management Technologies common stock.

     Visit www.celleraterx.com for more information.